High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
Allison Rosenthal, Anas Younes
https://pubmed.ncbi.nlm.nih.gov/27717585/Actively Recruiting
Led by Rong Tao · Updated on 2026-06-18
69
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the use of chidamide as a maintenance treatment for adults with newly diagnosed double-expressor diffuse large B-cell lymphoma DLBCL who have achieved complete response after induction therapy but still show minimal residual disease MRD detected by circulating tumor DNA ctDNA. This phase 2, prospective, multicenter, single-arm, open-label study focuses on patients at high risk of relapse despite initial success, as identified by persistent molecular disease. Chidamide is an oral drug that may have antitumor and immune-modulating effects in B-cell lymphomas. Participants will receive oral chidamide 20 mg on Days 1, 4, 8, and 11 of each 21-day cycle. ctDNA MRD will be tested every 12 weeks to monitor disease status. Treatment will continue until participants have two consecutive MRD-negative results at least 3 months apart, experience disease progression, encounter intolerable side effects, withdraw consent, or complete 2 years of maintenance therapy. This study does not include a control group and focuses on the single intervention of chidamide maintenance. During the study, participants will have regular assessments including ctDNA MRD testing every 12 weeks. Researchers will measure the rate of MRD negativity and progression-free survival at 2 years as main outcomes, along with event-free survival, overall survival, and safety. The study will monitor treatment-emergent adverse events up to 30 days after the last dose. Participants may stay in the trial for up to 2 years, with ongoing safety and efficacy evaluations throughout this period.
CONDITIONS
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
R
Rong Tao, MD & PhD
W
Wenhao Zhang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rong Tao
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants receive oral chidamide on Days 1, 4, 8, and 11 of each 21-day cycle. Treatment continues until two consecutive MRD-negative tests, disease progression, intolerable side effects, withdrawal, or completion of 2 years.
ctDNA MRD assessments every 12 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Allison Rosenthal, Anas Younes
https://pubmed.ncbi.nlm.nih.gov/27717585/Mark Roschewski, David M Kurtz, Jason R Westin...
https://pubmed.ncbi.nlm.nih.gov/40802906/Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore...
https://pubmed.ncbi.nlm.nih.gov/41428995/Nathalie A Johnson, Graham W Slack, Kerry J Savage...
https://pubmed.ncbi.nlm.nih.gov/22851565/Rong Tao
Lead Sponsor